JP2023505056A5 - - Google Patents
Info
- Publication number
- JP2023505056A5 JP2023505056A5 JP2022531006A JP2022531006A JP2023505056A5 JP 2023505056 A5 JP2023505056 A5 JP 2023505056A5 JP 2022531006 A JP2022531006 A JP 2022531006A JP 2022531006 A JP2022531006 A JP 2022531006A JP 2023505056 A5 JP2023505056 A5 JP 2023505056A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- cancer
- pharmaceutical composition
- composition according
- kras
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962941026P | 2019-11-27 | 2019-11-27 | |
| US62/941,026 | 2019-11-27 | ||
| US202062981822P | 2020-02-26 | 2020-02-26 | |
| US62/981,822 | 2020-02-26 | ||
| US202063005681P | 2020-04-06 | 2020-04-06 | |
| US63/005,681 | 2020-04-06 | ||
| PCT/US2020/062390 WO2021108682A1 (en) | 2019-11-27 | 2020-11-25 | Combination therapy involving diaryl macrocyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023505056A JP2023505056A (ja) | 2023-02-08 |
| JP2023505056A5 true JP2023505056A5 (https=) | 2023-12-05 |
| JP7670711B2 JP7670711B2 (ja) | 2025-04-30 |
Family
ID=76129920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022531006A Active JP7670711B2 (ja) | 2019-11-27 | 2020-11-25 | ジアリール大環状化合物を含む併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11654145B2 (https=) |
| EP (1) | EP4065125A4 (https=) |
| JP (1) | JP7670711B2 (https=) |
| KR (1) | KR20220133866A (https=) |
| CN (1) | CN114901286B (https=) |
| AU (1) | AU2020391222A1 (https=) |
| BR (1) | BR112022010278A2 (https=) |
| CA (1) | CA3162632A1 (https=) |
| IL (1) | IL293206A (https=) |
| MX (1) | MX2022006500A (https=) |
| TW (1) | TW202133855A (https=) |
| WO (1) | WO2021108682A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021154929A1 (en) * | 2020-01-31 | 2021-08-05 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| US20220323446A1 (en) * | 2021-03-17 | 2022-10-13 | Amgen Inc. | Sotorasib dosing regimen |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2025148858A1 (zh) * | 2024-01-08 | 2025-07-17 | 应世生物科技(南京)有限公司 | FAK抑制剂和Pan-RAS抑制剂 |
| WO2025157162A1 (zh) * | 2024-01-22 | 2025-07-31 | 应世生物科技(南京)有限公司 | Fak抑制剂与kras g12c抑制剂的联用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010319322A1 (en) * | 2009-11-13 | 2012-05-31 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| ES2933350T3 (es) * | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| AU2016287568B2 (en) * | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| RU2765181C2 (ru) * | 2015-07-06 | 2022-01-26 | Тёрнинг Поинт Терапьютикс, Инк. | Полиморфная форма диарильного макроцикла |
| EP3368039A1 (en) * | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| TWI808958B (zh) * | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| US20190134056A1 (en) * | 2017-03-10 | 2019-05-09 | The Trustees Of The Stevens Institute Of Technolog | K-ras mutations and antagonists |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| JP7060694B2 (ja) * | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| ES3017461T3 (en) | 2018-09-10 | 2025-05-13 | Mirati Therapeutics Inc | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer |
| CN110256421A (zh) * | 2019-06-26 | 2019-09-20 | 微境生物医药科技(上海)有限公司 | Kras-g12c抑制剂 |
| MX2022006366A (es) * | 2019-11-27 | 2022-06-22 | Turning Point Therapeutics Inc | Terapia de combinacion que implica compuestos de diarilo macrociclico. |
| WO2021148581A1 (en) * | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
-
2020
- 2020-11-25 BR BR112022010278A patent/BR112022010278A2/pt unknown
- 2020-11-25 IL IL293206A patent/IL293206A/en unknown
- 2020-11-25 TW TW109141454A patent/TW202133855A/zh unknown
- 2020-11-25 EP EP20894516.2A patent/EP4065125A4/en active Pending
- 2020-11-25 KR KR1020227021852A patent/KR20220133866A/ko active Pending
- 2020-11-25 CN CN202080089330.6A patent/CN114901286B/zh active Active
- 2020-11-25 US US17/104,752 patent/US11654145B2/en active Active
- 2020-11-25 AU AU2020391222A patent/AU2020391222A1/en active Pending
- 2020-11-25 JP JP2022531006A patent/JP7670711B2/ja active Active
- 2020-11-25 WO PCT/US2020/062390 patent/WO2021108682A1/en not_active Ceased
- 2020-11-25 CA CA3162632A patent/CA3162632A1/en active Pending
- 2020-11-25 MX MX2022006500A patent/MX2022006500A/es unknown
-
2023
- 2023-04-24 US US18/138,644 patent/US20240033266A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023505056A5 (https=) | ||
| CN115279376A (zh) | 用于治疗异常细胞生长的组合疗法 | |
| CN104519887B (zh) | 包含B‑Raf抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合 | |
| RU2754452C2 (ru) | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака | |
| JP2016535756A (ja) | ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法 | |
| Hedayat et al. | Selumetinib: a selective MEK1 inhibitor for solid tumor treatment | |
| CN105209073A (zh) | 包含B-Raf抑制剂和第二抑制剂的组合疗法 | |
| CN111818925B (zh) | Cdk4/6抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途 | |
| JP2019511526A (ja) | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 | |
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| CN1674938A (zh) | 用于治疗癌症的vegf受体酪氨酸激酶抑制剂的组合 | |
| CN102665711A (zh) | 青蒿素基药物与其他化学治疗剂的抗癌组合物 | |
| CN112218639A (zh) | 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合组合物和其使用方法 | |
| CN112043702A (zh) | 用于联合治疗结直肠癌的喹啉类化合物 | |
| JP2025540925A (ja) | 癌の治療におけるアゼノセルチブの断続的投与レジメン | |
| CN110636862B (zh) | 用于治疗乳腺癌的组合疗法 | |
| Juric et al. | A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2–) metastatic breast cancer | |
| EP3125901B1 (en) | Derivatives of cephalosporin for treating cancer | |
| CN105283178A (zh) | 用于治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合 | |
| TWI771344B (zh) | 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途 | |
| CA2912830A1 (en) | Specific cancer treatment regimens with ganetespib | |
| CN107137407B (zh) | 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途 | |
| KR20220007146A (ko) | 연부조직 육종의 조합 치료에 사용되는 퀴놀린 유도체 | |
| TW200922595A (en) | Organic compounds | |
| RU2777519C2 (ru) | Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы |